LAUSR

Leishmaniasis is a neglected tropical disease caused by the protozoan parasite Leishmania. It is endemic in more than 89 different countries worldwide. Sterol alpha‐14 demethylase (LdSDM), a sterol biosynthetic pathway enzyme in Leishmania donovani, plays an essential role in parasite survival and proliferation. Here, we used a drug repurposing approach to virtually screen the library of the Food and Drug Administration (FDA)‐approved drugs against LdSDM to identify the potential lead‐drug against leishmaniasis. Zafirlukast and avodart showed the best binding with LdSDM. Zafirlukast was tested for in vitro antileishmanial assay, but no significant effect on L. donovani promastigotes was observed even at higher concentrations. On the other hand, avodart profoundly inhibited parasite growth at relatively lower concentrations. Further, avodart showed a significant decrease in the number of intra‐macrophagic amastigotes. Avodart‐induced reactive oxygen species (ROS) in the parasites in a dose‐dependent manner. ROS induced by avodart led to the induction of apoptosis‐like cell death in the parasites as observed through annexin V/PI staining. Here, for the first time, we reported the antileishmanial activity and its possible mechanism of action of FDA‐approved drug, avodart, establishing a nice example of the drug‐repurposing approach. Our study suggested the possible use of avodart as an effective antileishmanial agent after further detailed validations.